Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide
Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate fr...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2004-07, Vol.80 (1), p.94-96 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 1 |
| container_start_page | 94 |
| container_title | International journal of hematology |
| container_volume | 80 |
| creator | STEIN, Gideon Y ZEIDMAN, Aliza FRADIN, Zinaida VARON, Meir COHEN, Amos MITTELMAN, Moshe |
| description | Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate from 10% to greater than 90%. Still, a subset of patients with resistant TTP fail to respond to plasmapheresis or remain dependent on this procedure. We report such a patient who was successfully treated with rituximab and cyclophosphamide. She has now been disease free for more than 6 months. This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP. |
| doi_str_mv | 10.1532/IJH97.E0403 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_217382914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1879945591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-ffe2c02d6b280ef3d202927d15beaa02c54071584df1e3da707da096518c9d783</originalsourceid><addsrcrecordid>eNpFkM1LwzAUwIMobk5P3qUInqTzJWma9ihjusnAy7xa0nzQjrWpSYruv7duk8GD98GP9x4_hG4xTDGj5Gn5tsj5dA4J0DM0xlnKYsp5co7GkBMWM45hhK683wBgDgm_RCPMSE4Z52P0uXZahEa3IbImctrXPoihCZWzTWlDLf9LuQu20-0w6Ho3hIi-61BFrg79T92IMhKtiuRObm1XWd9VoqmVvkYXRmy9vjnmCfp4ma9ni3j1_rqcPa9iSXMWYmM0kUBUWpIMtKGKAMkJV5iVWgggkiXAMcsSZbCmSnDgSkCeMpzJXPGMTtD9YW_n7FevfSg2tnftcLIgmNOM5DgZoMcDJJ313mlTdG743O0KDMWfymKvstirHOi748q-bLQ6sUd3A_BwBISXYmucaGXtT1wKmCYM018Agn00</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217382914</pqid></control><display><type>article</type><title>Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>STEIN, Gideon Y ; ZEIDMAN, Aliza ; FRADIN, Zinaida ; VARON, Meir ; COHEN, Amos ; MITTELMAN, Moshe</creator><creatorcontrib>STEIN, Gideon Y ; ZEIDMAN, Aliza ; FRADIN, Zinaida ; VARON, Meir ; COHEN, Amos ; MITTELMAN, Moshe</creatorcontrib><description>Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate from 10% to greater than 90%. Still, a subset of patients with resistant TTP fail to respond to plasmapheresis or remain dependent on this procedure. We report such a patient who was successfully treated with rituximab and cyclophosphamide. She has now been disease free for more than 6 months. This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1532/IJH97.E0403</identifier><identifier>PMID: 15293577</identifier><language>eng</language><publisher>Tokyo: Springer</publisher><subject>Adult ; Anemias. Hemoglobinopathies ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; Biological and medical sciences ; Cyclophosphamide - administration & dosage ; Diseases of red blood cells ; Drug Resistance ; Female ; Hematologic and hematopoietic diseases ; Humans ; Medical sciences ; Platelet Count ; Platelet diseases and coagulopathies ; Purpura, Thrombotic Thrombocytopenic - drug therapy ; Rituximab</subject><ispartof>International journal of hematology, 2004-07, Vol.80 (1), p.94-96</ispartof><rights>2004 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-ffe2c02d6b280ef3d202927d15beaa02c54071584df1e3da707da096518c9d783</citedby><cites>FETCH-LOGICAL-c395t-ffe2c02d6b280ef3d202927d15beaa02c54071584df1e3da707da096518c9d783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16013451$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15293577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEIN, Gideon Y</creatorcontrib><creatorcontrib>ZEIDMAN, Aliza</creatorcontrib><creatorcontrib>FRADIN, Zinaida</creatorcontrib><creatorcontrib>VARON, Meir</creatorcontrib><creatorcontrib>COHEN, Amos</creatorcontrib><creatorcontrib>MITTELMAN, Moshe</creatorcontrib><title>Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate from 10% to greater than 90%. Still, a subset of patients with resistant TTP fail to respond to plasmapheresis or remain dependent on this procedure. We report such a patient who was successfully treated with rituximab and cyclophosphamide. She has now been disease free for more than 6 months. This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP.</description><subject>Adult</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents, Alkylating - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Biological and medical sciences</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Diseases of red blood cells</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Platelet Count</subject><subject>Platelet diseases and coagulopathies</subject><subject>Purpura, Thrombotic Thrombocytopenic - drug therapy</subject><subject>Rituximab</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkM1LwzAUwIMobk5P3qUInqTzJWma9ihjusnAy7xa0nzQjrWpSYruv7duk8GD98GP9x4_hG4xTDGj5Gn5tsj5dA4J0DM0xlnKYsp5co7GkBMWM45hhK683wBgDgm_RCPMSE4Z52P0uXZahEa3IbImctrXPoihCZWzTWlDLf9LuQu20-0w6Ho3hIi-61BFrg79T92IMhKtiuRObm1XWd9VoqmVvkYXRmy9vjnmCfp4ma9ni3j1_rqcPa9iSXMWYmM0kUBUWpIMtKGKAMkJV5iVWgggkiXAMcsSZbCmSnDgSkCeMpzJXPGMTtD9YW_n7FevfSg2tnftcLIgmNOM5DgZoMcDJJ313mlTdG743O0KDMWfymKvstirHOi748q-bLQ6sUd3A_BwBISXYmucaGXtT1wKmCYM018Agn00</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>STEIN, Gideon Y</creator><creator>ZEIDMAN, Aliza</creator><creator>FRADIN, Zinaida</creator><creator>VARON, Meir</creator><creator>COHEN, Amos</creator><creator>MITTELMAN, Moshe</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20040701</creationdate><title>Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide</title><author>STEIN, Gideon Y ; ZEIDMAN, Aliza ; FRADIN, Zinaida ; VARON, Meir ; COHEN, Amos ; MITTELMAN, Moshe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-ffe2c02d6b280ef3d202927d15beaa02c54071584df1e3da707da096518c9d783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents, Alkylating - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Biological and medical sciences</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Diseases of red blood cells</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Platelet Count</topic><topic>Platelet diseases and coagulopathies</topic><topic>Purpura, Thrombotic Thrombocytopenic - drug therapy</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEIN, Gideon Y</creatorcontrib><creatorcontrib>ZEIDMAN, Aliza</creatorcontrib><creatorcontrib>FRADIN, Zinaida</creatorcontrib><creatorcontrib>VARON, Meir</creatorcontrib><creatorcontrib>COHEN, Amos</creatorcontrib><creatorcontrib>MITTELMAN, Moshe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEIN, Gideon Y</au><au>ZEIDMAN, Aliza</au><au>FRADIN, Zinaida</au><au>VARON, Meir</au><au>COHEN, Amos</au><au>MITTELMAN, Moshe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide</atitle><jtitle>International journal of hematology</jtitle><addtitle>Int J Hematol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>80</volume><issue>1</issue><spage>94</spage><epage>96</epage><pages>94-96</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate from 10% to greater than 90%. Still, a subset of patients with resistant TTP fail to respond to plasmapheresis or remain dependent on this procedure. We report such a patient who was successfully treated with rituximab and cyclophosphamide. She has now been disease free for more than 6 months. This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP.</abstract><cop>Tokyo</cop><pub>Springer</pub><pmid>15293577</pmid><doi>10.1532/IJH97.E0403</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2004-07, Vol.80 (1), p.94-96 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_217382914 |
| source | MEDLINE; Springer Online Journals |
| subjects | Adult Anemias. Hemoglobinopathies Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents - administration & dosage Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Cyclophosphamide - administration & dosage Diseases of red blood cells Drug Resistance Female Hematologic and hematopoietic diseases Humans Medical sciences Platelet Count Platelet diseases and coagulopathies Purpura, Thrombotic Thrombocytopenic - drug therapy Rituximab |
| title | Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A35%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20resistant%20thrombotic%20thrombocytopenic%20purpura%20with%20rituximab%20and%20cyclophosphamide&rft.jtitle=International%20journal%20of%20hematology&rft.au=STEIN,%20Gideon%20Y&rft.date=2004-07-01&rft.volume=80&rft.issue=1&rft.spage=94&rft.epage=96&rft.pages=94-96&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1532/IJH97.E0403&rft_dat=%3Cproquest_cross%3E1879945591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217382914&rft_id=info:pmid/15293577&rfr_iscdi=true |